JPMorgan Maintains Axalta at Neutral, Raises Price Target to $34
JPMorgan raised its price target from $33 to $34 while maintaining its Neutral rating. Axalta closed at $34.07 on Oct. 30.
JPMorgan raised its price target from $33 to $34 while maintaining its Neutral rating. Axalta closed at $34.07 on Oct. 30.